High-value dealmaking strengthens big pharma’s CNS ambitions Diseases of the central nervous system continue to catalyze dealmaking as companies search for new therapies to tackle some major unmet medical needs. (August 22, 2022) | By Raveena Bhambra. Several high-value licensing deals or acquisitions made in 2022 in the central nervous system (CNS) therapeutic area involve
By Marcia Santos Sadler, August 5, 2022. Biosortia is busy mining, not Bitcoin but, Microbes. Biosortia is doing what works in a way nobody ever thought possible or scalable. By providing target-hitting small molecules and datasets using deep access to previously unculturable microbes and their molecules. A valuable and proven source for the future of therapeutics.
